Recovery First Treatment Center's New Executive Director Pledges to Expand Access, Strengthen Addiction Treatment Services
HOLLYWOOD, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- As the overdose crisis continues to affect communities across South Florida, Recovery First Treatment Center has appointed Mercy Estevez, MSW, LCSW, as its new executive director. With over 15 years of experience in healthcare leadership, Estevez is committed to expanding access to life-saving addiction treatment and enhancing the quality of care for individuals struggling with substance use disorders and co-occurring mental health conditions.
'I am honored to lead an organization that has been a beacon of hope for so many individuals and families,' Estevez said. 'Addiction impacts entire communities, and it's critical that those in need have access to compassionate, high-quality care.'
A Proven Leader in Addiction Treatment
Before joining Recovery First, Estevez held pivotal executive roles at leading healthcare institutions. She has served as the CEO for Universal Health Services (UHS) across Memphis, Dallas, and North Carolina and held prominent leadership positions within the Oglethorpe Hospital System in Florida. She is a licensed clinical social worker (LCSW), holds a Master of Social Work (MSW) from Florida International University, and is recognized as a qualified supervisor in Florida. Throughout her career she has focused on improving patient outcomes, expanding treatment options, and optimizing service delivery.
'Recovery First has a strong foundation, and I am excited to build on its legacy. The team's unwavering dedication—many serving for years—truly inspires me. I've seen firsthand their dedication to ensure our patients have the best chance at long-term recovery. I look forward to working alongside them to elevate our impact and serve even more in our community and beyond.'
Expanding Access to Life-Saving Treatment
Recovery First has treated more than 11,000 patients struggling with addiction and co-occurring disorders over the years. The facility offers a full continuum of care including medical detox, residential rehab, and outpatient treatment, as well as specialized programming for Veterans, healthcare professionals, and those wishing to detox from methadone.
Under Estevez's leadership, the center will also focus on expanding community outreach efforts and strengthening partnerships with local healthcare providers and advocacy organizations. By forging these connections, she hopes to reach more individuals struggling with substance use disorders before their situation becomes critical.
'Our mission is simple yet profound,' she said. 'We restore hope and empower individuals and families impacted by addiction. United by compassion and a commitment to inclusive care, we provide a foundation for lasting recovery.'
About Recovery First Treatment Center
Recovery First Treatment Center, located in Hollywood, FL, serves the Miami-Fort Lauderdale area and individuals nationwide with evidence-based addiction treatment. We provide a full continuum of inpatient and outpatient services for individuals facing substance use and co-occurring mental health disorders. We believe in the power of recovery and are committed to restoring hope, empowering individuals and families, and breaking the stigma of addiction. Our specialized programs, including tailored support for Veterans and healthcare professionals, offer a strong foundation for lasting recovery that transforms lives. Recovery First Treatment Center is part of American Addiction Centers, a national leader in addiction treatment. Learn more at recoveryfirst.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Genetic Testing Market Research 2025: Genetic Discoveries Creating New Diagnostic Markets
Discover opportunities and pitfalls in the booming Genetic Testing industry, driven by advances in genetics and lower costs. Explore breakthroughs in Predictive Diagnostics, Pharmacogenomic Testing, and Direct-to-Consumer models across 14 countries and 5 regions. Get insights and forecasts to guide informed investment decisions. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Genetic Testing Markets. Global Market Analysis with Forecasts by Applications, Technologies, Products and Users with Executive and Consultant Guides" has been added to offering. The genetic testing industry is experiencing unprecedented growth, with its potential proving boundless as it expands across various sectors. This growth is being propelled by advancements in our understanding of the genetic basis of health and disease, coupled with decreasing costs. These factors are causing a surge in demand and development within the genetic testing market, presenting both opportunities and challenges. The industry's expansion is significantly influenced by the increasing realization that specific genetic profiles are crucial for the efficacy of novel therapies. Pharmacogenomics is establishing a foothold, underscoring the necessity for genetic testing to tailor drug therapies to individual genetic compositions. As this field grows, it fosters an increasing array of tests, boosting the volume of the traditional genetic testing market and its scope, while also introducing new complexities. The report examines these trends, providing detailed analyses across 14 countries and five regions. It highlights predictive diagnostics, pharmacogenomic testing, and the burgeoning direct-to-consumer segment, offering insights into the technology underpinning the industry. By doing so, it demystifies the complexities, presenting clear information on industry dynamics, opportunities, and challenges. With this comprehensive understanding, stakeholders can anticipate growth patterns and market forecasts over the next five years. The insights provided arm industry experts, investors, and decision-makers with the necessary knowledge to make informed investment decisions and valuations. In a rapidly evolving market, staying informed with the latest data is essential for maintaining a competitive advantage. Key Topics Covered: 1 Market Guides1.1 Genetic Testing - Strategic Situation Analysis & Company Rankings1.2 Guide for Executives, Marketing, Sales and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition 2.1 Genetic Testing Definition in This Report 2.2 The Genomics Revolution2.3 Market Definition2.4 Methodology2.5 Perspective: Healthcare and the IVD Industry2.6 Chromosomes, Genes and Epigenetics 3 Market Overview 3.1 Players in a Dynamic Market3.2 Genetic Tests - Types, Examples and Discussion3.3 Industry Structure 4 Market Trends4.1 Factors Driving Growth 4.1.1 Genetic Discoveries Creating New Diagnostic Markets4.1.2 The Aging Effect4.1.3 Pharmacogenomics Drives Further Growth4.1.4 Oncology and Liquid Biopsy Enter New Era4.1.5 Fertility Practice Growth drives market4.1.6 Direct to Consumer begins to break out 4.2 Factors Limiting Growth4.2.1 Increased Competition Lowers Price 4.2.2 Lower Costs4.2.3 Testing usage analysis curtailing growth 4.2.4 Wellness has a downside4.3 Instrumentation, Automation and Diagnostic Trends4.3.1 Traditional Automation and Centralization 4.3.2 The New Automation, Decentralization and Point of Care 4.3.3 Instruments Key to Market Share4.3.4 Bioinformatics Plays a Role 4.3.5 PCR Takes Command 4.3.6 Next Generation Sequencing Fuels a Revolution 4.3.7 NGS Impact on Pricing4.3.8 Whole Genome Sequencing, A Brave New World4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment 4.3.10 Shifting Role of Diagnostics 5 Genetic Testing Recent Developments5.1 Recent Developments5.1.1 Importance of This Section 5.1.2 How to Use This Section 5.2 Novitas Rescinds Coverage for Multiple Genetic Tests5.3 PerkinElmer (now Revvity) Becomes Dx Life Science Firm 5.4 New POC Genotyping Tests Based on Electromagnetic Detection 5.5 GenoMe Dx Launching dPCR Cancer Test 5.6 mDetect To Trial Breast Cancer Liquid Biopsy5.7 Genomics England, Aims to Sequence 100K Newborns 5.8 Juno Diagnostics NIPT With At-Home Sample Collection 5.9 Cardio Diagnostics Launches Genetic Cario Risk Test 5.10 Universal Genetic Testing in Breast Cancer Further Supported5.11 Aniling Gets CE-IVD Marks for Cancer Sequencing Tests 5.12 MyOme Lands Investment for WGS5.13 Type 2 Diabetes GWAS Enables Risk Prediction 5.14 LetsGetChecked to Acquire Veritas Genetics 5.15 Guardant Health Plans New Comprehensive Assay 5.16 Tesis Labs Raises $20M 5.17 Sema4: Sema4 Elements 5.18 Clarified Precision Medicine Acquires Interpares Biomedicine5.19 Genetic Technologies to Acquire DTC Genetic Test Provider EasyDNA 5.20 Illumina, Belgium Genetic Centers Partner on WGS-Based Dx5.21 NIH, Genomics England Launch Sequencing Studies Using Nanopore Technology5.22 Progenity Revenues Fall on COVID-19 Effect 5.23 Natera Launches Tumor Genomic Profiling Assay5.24 23andMe To Go Public5.25 Guardant Health to Offer Tumor Tissue Sequencing 5.26 Ancestry Quits Health Offering5.27 DTC Firm MyDNA Merges With Gene by Gene 5.28 Aetna Coverage for NIPT to Include All Pregnancies5.29 Agios Pharmaceuticals, PerkinElmer Partner on Hereditary Anemia Genetic Testing5.30 Tumor, Germline Testing of Cancer Patients Can Give Discordant Results 6 Profiles of Key Companies6.1 10x Genomics, Inc. 6.2 23andME Inc.6.3 Abbott Laboratories 6.4 Adaptive Biotechnologies 6.5 Admera Health, LLC6.6 Agilent/Dako6.7 Akonni Biosystems6.8 Amoy Diagnostics Co., Ltd. 6.9 LLC6.10 Anchor Dx 6.11 Arc Bio 6.12 Arrayit Corporation 6.13 ARUP Laboratories6.14 Aus Diagnostics6.15 BaseClear 6.16 Baylor Miraca Genetics Laboratories 6.17 Beckman Coulter Diagnostics 6.18 Becton, Dickinson and Company 6.19 BGI Genomics Co. Ltd 6.20 Bioarray Genetics 6.21 Biocept, Inc. 6.22 Biodesix Inc. 6.23 BioFluidica 6.24 BioGenex 6.25 Biolidics Ltd6.26 bioMerieux Diagnostics6.27 Bioneer Corporation6.28 Bio-Rad Laboratories, Inc6.29 Bio-Techne6.30 C2i Genomics 6.31 CareDx 6.32 Caris Molecular Diagnostics6.33 CellMax Life 6.34 Centogene 6.35 Cepheid (Danaher) 6.36 Circulogene 6.37 Clinical Genomics6.38 Color Genomics 6.39 Complete Genomics, Inc. - A BGI Company 6.40 CosmosID 6.41 Dante Labs.6.42 Datar Cancer Genetics Limited 6.43 Diasorin S.p.A. 6.44 Element Biosciences6.45 Element Biosciences6.46 Epic Sciences6.47 Epigenomics AG.6.48 Eurofins Scientific 6.49 Excellerate Bioscience 6.50 Fabric Genomics 6.51 Freenome 6.52 Fujirebio 6.53 Fulgent Genetics 6.54 Gene by Gene, Ltd. 6.55 Genedrive 6.56 GeneFirst Ltd.6.57 Genetron Holdings 6.58 Genomics England 6.59 Genomics Personalized Health (GPH)6.60 GenomOncology 6.61 Genzyme Corporation 6.62 Grifols 6.63 Guardant Health 6.64 Guardiome 6.65 HeiScreen 6.66 Helix 6.67 Helix OpCo6.68 Helomics6.69 Hologic 6.70 HTG Molecular Diagnostics 6.71 Human Longevity, Inc. 6.72 iCellate 6.73 Illumina 6.74 Incell Dx 6.75 Inivata 6.76 Integrated Diagnostics6.77 Invitae Corporation 6.78 Invivoscribe 6.79 Karius 6.80 Letsgetchecked 6.81 Lunglife AI Inc 6.82 Macrogen 6.83 MDNA Life SCIENCES, Inc.6.84 MDx Health 6.85 Medgenome6.86 Menarini Silicon Biosystems 6.87 Meridian Bioscience 6.88 Mesa Biotech (Thermo Fisher) 6.89 Mesa Laboratories, Inc. 6.90 Metabiomics Corp 6.91 miR Scientific 6.92 MNG Labs 6.93 NantHealth, Inc. 6.94 Natera 6.95 Nebula Genomics6.96 NeoGenomics 6.97 New England Biolabs, Inc. 6.98 NGeneBio6.99 Novogene Bioinformatics Technology Co., Ltd.6.100 Omega Bioservices 6.101 Oncocyte6.102 OncoDNA 6.103 OpGen 6.104 ORIG3N, Inc. 6.105 Origene Technologies 6.106 Oxford Nanopore Technologies 6.107 Pacific Biosciences 6.108 Panagene 6.109 PathoQuest S.A. 6.110 Perkin Elmer (now Revvity) 6.111 Personal Genome Diagnostics6.112 Personalis.6.113 Precipio 6.114 PrecisionMed6.115 Promega 6.116 Protagen Diagnostics 6.117 Qiagen 6.118 QuantuMDx 6.119 Roche Molecular Diagnostics 6.120 Roswell Biotechnologies 6.121 Seegene6.122 Sema4 Holdings6.123 6.124 Siemens Healthineers 6.125 simfo GmbH 6.126 Singlera Genomics Inc.6.127 Singular Genomics 6.128 SkylineDx 6.129 Standard BioTools 6.130 Sure Genomics, Inc. 6.131 Sysmex 6.132 Sysmex Inostics6.133 Tempus Labs, Inc. 6.134 Thermo Fisher Scientific Inc. 6.135 Ultima Genomics 6.136 Ultima Genomics 6.137 Variantyx 6.138 Vela Diagnostics 6.139 Volition 6.140 Vyant Bio 6.141 Zymo Research Corp 7 Global Market Size7.1 Global Market by Country7.2 Global Market by Application7.3 Global Market by Technology7.4 Global Market by Product7.5 Global Market by User 8 Market Sizes by Application8.1 Newborn Testing Market8.2 NIPT Market8.3 Predictive Testing Market8.4 Oncology Testing Market8.5 DTC Testing Market8.6 Other Testing Market 9 Global Genetic Testing Market by Technology9.1 PCR Testing Market9.2 NGS Market9.3 Cytogenetic Testing Market9.4 Other Testing Market 10 Global Genetic Testing Market by Product10.1 Instruments Market10.2 Reagents and Kits Market10.3 Software Market10.4 Services Market 11 Global Genetic Testing Market by User11.1 Academic Market11.2 Clinical Market11.3 Pharmaceutical Market11.4 Industrial and Other Market 12 The Future of Genetic Testing 13 Appendices13.1 United States Medicare System: Laboratory Fees Schedule13.2 The Most Used IVD Assays 13.3 The Highest Grossing Assays For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Single Cell Genomics Market Research 2025: Immuno-oncology, Research Range, Technology Maturity & Convergence, Declining Costs Bolster Growth
Discover the potential of Single Cell Genomics in our latest report. As it revolutionizes healthcare, identify opportunities, growth expectations, and market potential. Stay ahead with insights into this booming field that is redefining genomics and biotechnology. Ideal for management teams. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Single Cell Genomics Markets: Forecasts by Analyte, Product, Workflow, User, Application and Country with Executive and Consultant Guides" has been added to offering. The market for SCG is experiencing a notable surge as it opens new doors in understanding the genomics of individual cells. This leap forward in biotechnology not only inspires fresh discoveries but also enhances our approach to personalized medicine and precision healthcare. Key stakeholders in the healthcare and biotechnology industries should take note of the opportunities SCG presents, from improving patient outcomes to developing innovative therapeutic strategies. This report is designed to equip management teams with insights into the pivotal developments in SCG, including technological advancements and the accompanying strategic opportunities. As the SCG technology outpaces current market expectations, it's crucial for business leaders to stay informed about the potential opportunities and pitfalls that accompany this rapid evolution. The report sheds light on growth expectations, possible market size, and the interplay between genomics, immunology, and SCG, aiding readers in making informed strategic decisions. Single Cell Genomics (SCG) is revolutionizing the scientific research and development landscape, offering transformative insights across healthcare and biotechnology sectors. This digital press release outlines the findings of a comprehensive new report exploring whether SCG could potentially replace traditional genomics. The implications of SCG are vast, with applications extending from identifying novel life forms to uncovering new diseases and pioneering cures. As the technology continues to evolve, its footprint in clinical applications is expanding, driving substantial market growth. As SCG continues to transition from laboratory research to practical clinical applications, understanding its potential impact on the market becomes increasingly important. This press release invites stakeholders to delve into the report for a thorough analysis of the technological trajectory, market dynamics, and future prospects of SCG. By doing so, they can harness the technology's potential, ensure competitive edge, and contribute to the broader goal of advancing human health. Key Topics Covered: 1 Market Guides1.1 Situation Analysis1.2 Guide for Executives and Marketing Staff1.3 Guide for Investment Analysts and Management Consultants 2 Introduction and Market Definition2.1 What is Single Cell Genomics?2.2 SCG - Still Early Days2.3 Market Definition2.4 Methodology2.5 Sizing the Genome - Not What You Think 3 Single Cell Genomics - Guide to Technology3.1 Isolating Single Cells3.1.1 FACS3.1.2 LCM3.1.3 Micromanipulators3.1.4 Microfluidics3.2 Amplification3.2.1 WTA - Whole Transcriptome Amplification3.2.2 WGA - Whole Genome Amplification3.3 PCR3.4 NGS3.5 Microarray3.6 Digital Spatial Profiling (DSP) Technology 4 Industry Overview4.1 Academic Research Lab4.2 Diagnostic Test Developer4.3 Instrumentation Supplier4.4 Chemical/Reagent Supplier4.5 Pathology Supplier4.6 Independent Clinical Laboratory4.7 Public National/regional Laboratory4.8 Hospital Laboratory4.9 Physicians Office Lab (POLS)4.10 Audit Body4.11 Certification Body 5 Market Trends5.1 Factors Driving Growth5.1.1 Immuno-oncology5.1.2 Research Range5.1.3 Technology Maturity & Convergence5.1.4 Declining Costs5.2 Factors Limiting Growth5.2.1 Competition5.2.2 Instrument Integration5.2.3 Technology Shift5.2.4 Technology Limitations5.3 Technology Development5.3.1 Spatial Profiling5.3.2 Integration5.3.3 Big Data5.3.4 Kits and Commodities5.4 Instrumentation, Automation and Diagnostic Trends5.4.1 Traditional Automation and Centralization5.4.2 The New Automation, Decentralization and Point Of Care5.4.3 Instruments Key to Market Share5.4.4 Bioinformatics Plays a Role5.4.5 PCR Takes Command5.4.6 Next Generation Sequencing Fuels a Revolution5.4.7 NGS Impact on Pricing5.4.8 Whole Genome Sequencing, A Brave New World5.4.9 Companion Diagnostics Blurs Diagnosis and Treatment5.4.10 Shifting Role of Diagnostics 6 Single Cell Genomics Recent Developments6.1 Recent Developments - Importance and How to Use This Section6.1.1 Importance of These Developments6.1.2 How to Use This Section6.2 Scale Biosciences announces ScalePlex to simplify single cell genomics6.3 10x Genomics Launches 5,000-Plex Gene Panel for Xenium6.4 NIH researchers develop AI drug matching tool6.5 Curio Bioscience to Transform Single-Cell Sequencing Data into Spatial Context .. 1536.6 Factorial Biotechnologies Unveils Mosaic6.7 Deepcell and NVIDIA collaborate to advance AI in single cell research6.8 OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies6.9 Beckman Coulter and 10x Genomics partner6.10 MGI and Xpress Genomics to Advance Single-cell RNA-Sequencing6.11 Single-Cell Sequencing Reveals Traits in Cereal Crops6.12 Single-cell Genomics meets Human Genetics6.13 Singular Genomics Launches Kits for Single Cell Sequencing6.14 Scale Biosciences Introduces Disruptive Single-Cell Profiling Solutions6.15 Singleron showcases latest single cell sequencing technology6.16 Oxford Nanopore to Make Single-cell Sequencing Accessible to Any Laboratory . 1686.17 Single-Cell RNA-seq Method Enables Profiling Live Cells6.18 Novogene Launches New Single-Cell Lab6.19 New DNA Atlas Provides Clues for Heart Disease Risk6.20 BioSkryb Genomics Launches ResolveOME6.21 Parse Biosciences Expands Single-Cell Product Line6.22 Massively Multiplexed Single-Cell In Situ Spatial Genomics Now in U.S. Market6.23 Pfizer Centralizes Single Cell Data on Seven Bridges System6.24 Consortium to Standardize Single-Cell Sequencing6.25 Scienion, Cellenion Enter Licensing Deal6.26 Immunai Acquires Swiss Bioinformatics Firm Nebion6.27 Startup MiCareo Targets Rare Cell Isolation Market6.28 Parse Biosciences Lowers Cost Barriers to Single-Cell Transcriptomics6.29 Deepcell Advancing Tech for Single-Cell Genomics6.30 10x Genomics Outlines 2021 Growth Plans6.31 Single-Cell Genomics Firm Analytical Biosciences Inks Deal with BioMap6.32 IsoPlexis Features Cheaper, More Flexible Single-Cell Proteomic Systems6.33 DNTR-Seq Combines WGS, Transcriptomics in Single Cells6.34 BitBiome Builds Single-Cell Bacterial Sequencing Business6.35 S2 Genomics Signs Distribution Agreements for Asia-Pacific6.36 Single-Cell COVID-19 Study Investigates Immune Hyperactivation6.37 Levitas Bio to Launch Magnetic Levitation Cell Separation Platform6.38 Single-Cell and Spatial Genomics6.39 Single-Cell Genomics6.40 Namocell, Takara Bio, HepaTx Partner on Single-Cell Genomics6.41 Vizgen Launches With $14M Series A Financing6.42 SeqWell Raises $9M in Series B Round 7 Profiles of Key Single Cell Genomics Companies7.1 10x Genomics, Inc.7.2 Admera Health, LLC7.3 Agilent7.4 Beckman Coulter Diagnostics (Danaher)7.5 Becton, Dickinson and Company7.6 Berkley Lights7.7 BGI Genomics Co. Ltd7.8 BioGenex7.9 Bio-Rad Laboratories, Inc7.10 BioSkryb Genomics7.11 Bitbiome7.12 Bruker7.13 Cell Microsystems7.14 Cellenion (BICO)7.15 CellSorter7.16 Cytek Biosciences7.17 Cytena7.18 Deepcell7.19 Dolomite Bio (Unchained Labs)7.20 Element Biosciences7.21 Epic Sciences7.22 Fluent Biosciences7.23 Fluxion Biosciences (Cell Microsystems)7.24 Honeycomb Biotechnologies7.25 Illumina7.26 Incell Dx7.27 Leica Biosystems7.28 Menarini Silicon Biosystems7.29 MGI7.30 Miltenyi Biotec7.31 Mission Bio7.32 Myllia Biotechnology7.33 Namocell7.34 NanoCellect Biotechnology7.35 Nanostring7.36 New England Biolabs, Inc.7.37 Novogene7.38 Oxford Nanopore Technologies7.39 Pacific Biosciences7.40 Parse Biosciences7.41 Partek7.42 Qiagen7.43 Revvity7.44 Roche Diagnostics7.45 S2 Genomics7.46 Scale Biosciences7.47 Singleron Biotechnologies7.48 Singular Genomics7.49 Singulomics7.50 Sony Biotechnology7.51 Standard BioTools7.52 Stemcell Technologies7.53 Takara Bio7.54 Thermo Fisher Scientific7.55 Ultima Genomics7.56 Vizgen7.57 Watchmaker Genomics 8 Single Cell Genomics Global Market Size8.1 Global Market Overview by Country8.2 Global Market Size by Analyte - Overview8.3 Global Market by Product - Overview8.4 Global Market by Workflow - Overview8.5 Global Market by End User - Overview8.6 Global Market by Application - Overview 9 Global Market by Analyte9.1 DNA Market9.2 RNA Market9.3 Epigenetic Market9.4 Proteomic Market9.5 Multiomics Market 10 Single Cell Genomics Market by Product10.1 Instrument Market10.2 Reagent Market10.3 Software & Other Market 11 Single Cell Genomics Market by Workflow11.1 Cell Isolation Market11.2 Sample Preparation Market11.3 Genomic Analysis Market 12 Single Cell Genomics Market by End User12.1 Research Market12.2 BioPharma Market12.3 Clinical Market 13 Global Market by Application13.1 Oncology Market13.2 Immunology Market13.3 Microbiology Market13.4 Cell Market13.5 Stem Cell Market13.6 Neurology Market 14 Appendices14.1 FDA Cancer Drug Approvals by Year14.2 Clinical Trials Started Historical14.3 Prevalence of Cancer Treatments For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Antimicrobial Resistance Diagnostic Markets, Strategies and Trends Report 2025: Antimicrobial Resistance Spurs Innovation in Diagnostics and Opens Key Market Opportunities Across High-Burden Pathogens
Diagnostics drive progress against antimicrobial resistance by developing new technologies to diagnose pathogens and infections. Discover insights into the 6 Key Large Pathogen Opportunities, market forecasts, and profiles of over 30 companies leading the charge. Stay informed on this critical issue. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, With Executive Guides and Customization" has been added to offering. As antimicrobial resistance (AMR) continues to pose a significant threat to global health, innovative diagnostic technologies are taking center stage in the effort to mitigate this challenge. These advancements could potentially address the resistance dilemma even in the face of delayed development of new antibiotics. Cutting-edge diagnostic tools, surpassing traditional gene sequencing methods, are being researched and developed to seize the expanding market opportunities within this vital healthcare domain. In an extensive analysis, the publisher sheds light on the technological landscape, covering a variety of sophisticated approaches for diagnosing pathogens and infections. We have pinpointed six major pathogen-related opportunities, underscoring their importance in the diagnosis and treatment of infectious diseases. Furthermore, we offer detailed market forecasts to aid stakeholders in navigating this rapidly evolving field. The study profiles over 30 leading companies, from industry giants to emerging innovators, all dedicated to advancing diagnostic solutions in the face of AMR. These entities are leveraging new technologies to enhance the accuracy, efficiency, and speed of pathogen detection, which is crucial in managing infections and curbing the spread of resistance. With AMR limiting the efficacy of current antibiotics, the role of diagnostics becomes even more critical. Enhanced diagnostic tools not only aid in identifying appropriate treatments faster but also enable more precise use of antibiotics, thereby contributing to the global effort to fight resistance. Current and future diagnostic technologies promise healthcare professionals more robust options in the ongoing battle against AMR. By expanding the avenues for early detection and precise pathogen identification, these technologies are essential in managing infectious disease threats and influencing treatment outcomes. As the world continues to grapple with AMR and its implications on public health, the development and implementation of advanced diagnostic solutions stand as a beacon of hope. The strategic insights and comprehensive market forecasts provided in the publisher's study serve as valuable resources for stakeholders aiming to capitalize on the innovations reshaping the fight against infectious diseases. Key Topics Covered: 1 Market Guides 1.1 Antimicrobial Resistance - Strategic Situation Analysis1.2 Guide for Executives and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition2.1 The Threat and Opportunity of Antimicrobial Resistance2.2 Defining the Opportunity2.2.1 Revenue Market Size 2.3 Methods and Sources 2.3.1 Methodology2.3.2 Sources2.3.3 Authors 2.4 Perspective: Healthcare and the IVD Industry2.4.1 Global Healthcare Spending 2.5 Spending on Diagnostics2.5.1 Important Role of Insurance for Diagnostics 3 Overview of a Dynamic Market 3.1 Players in a Dynamic Market 3.1.1 Diagnostic Test Developer3.1.2 Instrumentation Supplier3.1.3 Chemical/Reagent Supplier 3.1.4 Pathology Supplier 3.1.5 Independent Clinical Laboratory3.1.6 Public National/regional Laboratory 3.1.7 Hospital Laboratory3.1.8 Physicians Office Lab (POLS)3.1.9 Audit Body 3.1.10 Certification Body 3.2 Understanding Antimicrobial Resistance 3.2.1 What is Antimicrobial Resistance (AMR) 3.2.2 Bacteria and Other Microbes 3.2.3 The History of Antibiotics3.2.4 The Role of Animal Husbandry3.2.5 The Implications of Horizontal Transfer 3.2.6 The Threat of AMR3.3 The Changing Road to New Antibiotics & Technologies 3.4 The Key Role of Diagnostics in AMR 4 The Market Opportunity of AMR 4.1 The Key Large Market Opportunities in AMR 4.1.1 Streptococcus Pneumoniae (DRSP)4.1.2 Campylobacter (DRC)4.1.3 Clostridium Difficile (CD)4.1.4 Staphylococcus aureus (MRSA) 4.1.5 Neisseria gonorrhoeae (DRNG)4.1.6 Salmonella (DRNTS)4.2 Diagnostic Technology Development Opportunities 4.2.1 What's Wrong with Microbiology 4.2.2 The Features Battleground of Infectious Disease Diagnostics4.2.3 Multiplex vs. POC/Rapid4.2.4 The Miracle of Genetics4.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation4.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing. 4.2.7 Markers of Resistance. 4.2.8 What Happens to the Microbiology Lab? 5 Antibiotic Resistance Diagnostics Recent Developments5.1 Antibiotic Resistance Recent Developments5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 FDA Clears New bioMerieux Diagnostic System and Panel5.3 Selux Diagnostics Phenotyping System Gets FDA Approval5.4 New diagnostics to tackle drug resistant infections 5.5 Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels 5.6 Three companies join forces to tackle antimicrobial resistance (AMR)5.7 T2 Biosystems Exercises BARDA Option 5.8 OpGen to Ramp up Use of Acuitas AMR Gene Panel 5.9 BD Partners With Pfizer, Wellcome to Study AMR Dx 5.10 Sepsis Test Developers Accelerate Plans 5.11 OpGen Receives FDA Clearance for AMR Panel 5.12 Visby Medical - Rapid Uptake of Handheld PCR Test for STIs5.13 MicroGenDx, OrthoKey Clinic and OrthoKey Surgery5.14 BioMerieux Receives CE Mark for Vitek Clinical Microbiology System 5.15 Hologic to Acquire Mobidiag5.16 Campylobacter strains exchange genes5.17 Disinfection spreads antimicrobial resistance 5.18 Molzym, Fraunhofer Developing Rapid Sepsis Dx 5.19 Illumina, IDbyDNA Build NGS-Based Respiratory Panel5.20 Accelerate Diagnostics Expands AMR Testing5.21 Rapid diagnostics linked to optimal antibiotics5.22 Visby Medical Wins AMR Diagnostic Competition 5.23 DNAe Technology SARS-CoV-2 Sequences 5.24 Infections with foodborne bacteria becoming harder to treat5.25 Dust is sharing antibiotic resistance genes 6 Key AMR Diagnostics Companies6.1 1928 Diagnostics6.2 Abacus Diagnostica 6.3 Abbott Laboratories6.4 Accelerate Diagnostics6.5 ADT Biotech6.6 Beckman Coulter Diagnostics 6.7 Becton, Dickinson and Company 6.8 Binx Health6.9 bioMerieux Diagnostics 6.10 Bio-Rad Laboratories, Inc.6.11 Cepheid (Danaher)6.12 Curetis N.V. / Curetis GmbH 6.13 Day Zero Diagnostics. 6.14 Enzo Biochem 6.15 Eurofins Scientific 6.16 Fusion Genomics.6.17 GeneFluidics 6.18 Genetic Signatures6.19 Great Basin Corporation6.20 Hologic6.21 Hutman Diagnostics6.22 Inflammatix 6.23 Linear Diagnostics.6.24 Lumos Diagnostics 6.25 Millipore Sigma 6.26 OpGen6.27 Ortho Clinical Diagnostics6.28 Perkin Elmer6.29 Qiagen6.30 Roche Molecular Diagnostics6.31 SeLux Diagnostics6.32 Sense Biodetection 6.33 Siemens Healthineers6.34 Sysmex 6.35 Thermo Fisher Scientific Inc. 6.36 Visby Medical 7 The Global Market for Antimicrobial Resistance Diagnostics 7.1 Global Market Overview by Country7.2 Global Market by Technology - Overview7.3 Global Market by Technology - Overview 8 Global Antibiotic Resistance Diagnostic Markets - By Pathogen8.1 Drug Resistant Streptococcus Pneumoniae - DRSP8.2 Drug Resistant Campylobacter - DRC8.3 Clostridium Difficile - CD8.4 Methicillin Resistant Staphylococcus Aureus - MRSA8.5 Drug Resistant Neisseria Gonorrhoeae - DRNG8.6 Drug Resistant Salmonella - DRNTS 9 Global Antibiotic Resistance Diagnostic Markets - by Technology9.1 Microbiology Culture9.2 Immunoassay9.3 PCR9.4 NGS9.5 Mass Spectrometry - MS9.6 Rapid and Point of Care - Rapid/POC 10 Vision of the Future of AMR Diagnostics 11 Appendices 11.1 United States Medicare System: Clinical Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
